title: [Association of anti synthetase syndrome and limited systemic sclerosis in a patient: successful treatment with rituximab].
authors.forename: Dalila
authors.initials: D
authors.lastname: Mrabet
authors.forename: Zeineb
authors.initials: Z
authors.lastname: Alaya
authors.forename: Héla
authors.initials: H
authors.lastname: Khiari
authors.forename: Inès
authors.initials: I
authors.lastname: Zaraa
authors.forename: Ines
authors.initials: I
authors.lastname: Chelly
authors.forename: Héla
authors.initials: H
authors.lastname: Sahli
authors.forename: Nihel
authors.initials: N
authors.lastname: Meddeb
authors.forename: Slaheddine
authors.initials: S
authors.lastname: Sellami
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001168:Arthritis / Q000150:complications / Q000188:drug therapy; D001284:Atrophy; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects; D007555:Isoxazoles / Q000009:adverse effects; D000077339:Leflunomide; D008025:Ligases / Q000378:metabolism*; D008727:Methotrexate / Q000009:adverse effects; D018482:Muscle, Skeletal / Q000473:pathology; D000069283:Rituximab; D045745:Scleroderma, Limited / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000473:pathology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007555:Isoxazoles; D000069283:Rituximab; D006886:Hydroxychloroquine; D008025:Ligases; D000077339:Leflunomide; D008727:Methotrexate